Rimegepant
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2020
- First approval year
- 2020
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Rimegepant
- Molecular weight
- 534.57
- Structure (SMILES)
- N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
- bhv 3000
- Bhv-3000
- bms 927711
- bms 927711 cgrp antagonist
- BMS-927711
- BMS-927711 (CGRP Antagonist)
- rimegepant
- Rimegepant
- Rimegepant [INN]
- Rimegepant [MI]
- Rimegepant [USAN]
- Rimegepant [WHO-DD]
- rimegepant inn
- rimegepant mi
- rimegepant usan
- rimegepant who dd
- ATC classification codes
- N02CD06
Sources for recorded values
- CAS registry numbers
- 1289023-67-1
- ChEMBL ID
- CHEMBL2178422
- InChIKey
- KRNAOFGYEFKHPB-ANJVHQHFSA-N
- PubChem compound IDs
- 51049968
- RxNorm IDs (RxCUI)
- 2282307
- FDA ingredient codes (UNII)
- 997WVV895X
- Applicant
- PFIZER
- Approval date
- 27 Feb 2020
- Application number
- NDA212728
- Status
- Authorised
- Status date
- 25 Apr 2022
- Authorisation date
- 25 Apr 2022
- Approved indications
- Vydura is indicated for the Acute treatment of migraine with or without aura in adults; Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.
- Product number
- EMEA/H/C/005725
- Authorisation holder
- Pfizer Europe MA EEIG
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- Yes
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Migraine Disorders
European medicines record
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- European Union (EMA)
- Authorised
- Pharmacology name
- rimegepant
- Type
- Synthetic organic
- Drug name stem
- -gepant
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- AMY1 receptor
- Gene symbol
- RAMP1
- Protein identifier
- O60894
- Median affinity
- 8.1
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- RAMP1
- Protein identifier
- O60894
- Median affinity
- 9.6
- Affinity units
- pKB
- Primary target
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- AMY1 receptor
- Gene symbol
- CALCR
- Protein identifier
- P30988
- Median affinity
- 8.1
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- CALCRL
- Protein identifier
- Q16602
- Median affinity
- 9.6
- Affinity units
- pKB
- Primary target
- Yes
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
- Action type
- Antagonist
- Target
- Calcitonin gene-related peptide type 1 receptor
- Protein identifier
- Q16602
Open Targets mechanisms
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
- Action type
- Antagonist
- Target
- Calcitonin gene-related peptide type 1 receptor
DrugCentral mechanisms
- Action type
- Antagonist
- Gene symbol
- CALCRL
- Protein identifier
- Q16602
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Irritable Bowel Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000555
- Subject identifier
- D043183
- Condition
- Psoriasis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Temporomandibular Joint Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005279
- Subject identifier
- D013705
- Condition
- Sinusitis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007486
- Subject identifier
- D012852
- Condition
- Trigeminal Neuralgia
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001219
- Subject identifier
- D014277
- Condition
- Migraine Disorders
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005277
- Subject identifier
- D008881
- Condition identifier
- EFO_0000555
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000676
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005279
- Highest recorded phase
- 3
- Condition identifier
- EFO_0007486
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008008
- Condition identifier
- EFO_1001219
- Highest recorded phase
- 2
- Condition identifier
- HP_0002027
- Highest recorded phase
- 2
- Condition identifier
- HP_0012531
- Highest recorded phase
- 2
- Condition identifier
- HP_0100582
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005052
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005277
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006031
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006314
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008599
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0021040
- Highest recorded phase
- 1
- Event
- decreased embryo viability
- Reports
- 1
- Reporting signal score
- 11.3267
- Event
- drug interaction
- Reports
- 3
- Reporting signal score
- 9.57925
- NCT01430442
- NCT01445067
- NCT03235479
- NCT03237845
- NCT03266588
- NCT03461757
- NCT03732638
- NCT04574362
- NCT04649242
- NCT04743141
- NCT05156398
- NCT05371652
- NCT05399459
- NCT05399485
- NCT05810038
- NCT03941834
- NCT04629950
- NCT05248997
- NCT05262517
- NCT05264714
- NCT06221111
- Dose
- 75 mg
- Route
- Oral
- How often
- As needed; every other day
Conditions of use
- Take with or without food
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 2
- Polar surface area
- 119.13
- Calculated partition coefficient (ALogP)
- 4.49
- Calculated partition coefficient (XLogP)
- 2.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 3
- Heavy atoms
- 39
- Molecular formula
- C28H28F2N6O3
- Monoisotopic mass
- 534.21909510
- Natural product
- No
- Recorded assays
- 1,171
- Active assays
- 7
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (61)
- A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment
- A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- A Prospective Real World Study of Rimegepant in the Treatment of Migraine
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
- A Randomized, Open-Label, Multi-Center Study of Vestibular Migraine Prevention: Rimegepant Versus Flunarizine Non-inferiority Study
- A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area
- A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
- A Study to Find Out if the Medicine Called Rimegepant is Safe for Adults in India
- A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants
- A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
- A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
- A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
- A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine
- A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- Acute Migraine Treatment in the ED With Gepants
- An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache
- An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
- ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
- Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine
- Cluster Headache Treatment With Rimegepant
In development for (12)
- Chronic rhinosinusitis Phase 3
- Colorectal cancer Phase 2
- Irritable bowel syndrome Phase 2
- Malignant pancreatic neoplasm Phase 1
- Migraine disorder Phase 3
- Nasal cavity polyp Phase 3
- Pancreatic ductal adenocarcinoma Phase 1
- Pancreatic neoplasm Phase 1
- Psoriasis Phase 2
- Sinusitis Phase 3
- Temporomandibular joint disorder Phase 3
- Trigeminal neuralgia Phase 2